• DSHS HIV/STD Program

    Post Office Box 149347, MC 1873
    Austin, Texas 78714

    Phone: 737-255-4300

    Email the HIV/STD Program

    Email HIV, STD, Hepatitis C, and TB data requests to the Program – This email can be used to request data and statistics on HIV, STDs, Hepatitis C, and TB in Texas. It cannot be used to get treatment or infection history for individuals, or to request information on programs and services. Please do not include any personal, identifying health information in your email such as HIV status, Date of Birth, Social Security Number, etc.

    For treatment/testing history, please contact your local health department.

    For information on HIV testing and services available to persons living with HIV, please contact your local HIV services organization.

MAC Meeting Minutes April 5, 2019


Texas HIV Medication Advisory Committee Meeting

Meeting Minutes
April 5, 2019
12:30 p.m.

Brown Heatly Building, Public Hearing Room
4900 N. Lamar Blvd.
Austin, Texas 78751


Table 1: Texas HIV Medication Advisory Committee (MAC) member attendance at the Friday, April 5, 2019 meeting.

MEMBER NAME

YES

NO

MEMBER NAME

YES

NO

Garcia, Fernando, M.D.

X

Rosas, Frank

X

Heresi, Gloria, M.D.

P

Tennison, Demetra

X

Keiser, Philip, M.D.

X

Turner, Bruce

X

Miertschin, Nancy, M.P.H.

X

Vanek, Natalie, M.D.

X

Moore, Clyde “Ray”

X

Rodriguez-Escobar, Yolanda, Ph.D.

X

P: Indicates participated by phone


Agenda Item 1 & 2: Call to Order/Welcome and Introductions

Dr. Philip Keiser called the meeting to order at 12:32 pm and welcomed all in attendance. Ms. Sallie Allen reviewed logistical announcements, conducted a roll call and announced a presence of a quorum.


Agenda Item 3: Approval of previous meeting minutes (January 18, 2019)

Dr. Keiser asked for approval of the meeting minutes for the January 18, 2019 Texas HIV Medication Advisory Committee.

Motion: Mr. Bruce Turner motioned for approval of January 18, 2019 meeting minutes with the noted corrections to Agenda items 4 and 5. Dr. Yolanda Rodriguez-Escobar seconded the motion. Dr. Phillip Keiser asked for a verbal vote, and the motion carried unanimously with eight yeas’, no nays, and no abstentions to accept the January 18, 2019 minutes.


Agenda Item 4: Discussion Item – Commissioners Update/Legislative Update

Mr. Felipe Garcia presented information regarding the current legislative session, including an overview of current bills, riders and proposed exceptional items that could affect the Department of State Health Services, and the Presidential Plan to End HIV.


Agenda Item 5: Discussion Item – Approval of non-MAC Sub-committee members

Dr. Phillip Keiser led discussion regarding approval of non-MAC subcommittee members. Highlights of the discussion and committee member discussion included:

  • The Data and Governance subcommittee recommended that requests to become subcommittee members be submitted to the Texas HIV Medication Program and the Medication Advisory Committee chair in the form of curriculum vitae and references. The MAC chair would then approve the subcommittee members. A motion to this effect was made by Yolanda Rodriguez-Escobar, and seconded by Dr. Natalie Vanek.


Agenda Item 6: Discussion Item, Action Item – Sub-Committee Reports (Governance and Data, and Formulary)

Highlights of the Governance and Data subcommittee discussion and committee member discussion included:

  • The process regarding the selection of the MAC Chair and Vice-Chair will be discussed and voted upon in the next Advisory Committee meeting.
  • The Data and Governance subcommittee will review standards for attendance and participation and present their conclusions to the Committee at the next meeting.

Highlights of the Formulary subcommittee discussion and evaluations of Delstrigo and Pifeltro medications and committee member discussion included:

  • On March 11, 2019, the subcommittee discussed the medications requested for addition to the formulary. The subcommittee recommended adding Delstrigo, Pifeltro, and SymfiLo, and that Symfi and Cymduo should not be added.
  • On April 2, 2019, the subcommittee discussed Vemlidy and Baraclude for the treatment of Hepatitis B, and recommended the addition of both to the formulary. The subcommittee also recommended the removal of Delavirdine and Indinavir from the formulary due to lack of utilization. These items will be added to the agenda for the next meeting.

Motion: Mr. Bruce Turner motioned to add Delstrigo and Pifeltro drug medications to the THMP drug formulary. Mr. Frank Rosas seconded the motion for the Delstrigo medication, and Dr. Natalie Vanek seconded the motion for the Pifeltro medication. Dr. Phillip Keiser asked for a verbal vote, and motions to add for both drug medications, Delstrigo and Pifeltro, carried unanimously with eight yea’s, no nays, and no abstentions.


Agenda Item 7: Action Item – Formulary Changes – Committee Review and Vote Required

Dr. Juan Daniel Verdi Ortiz, with Mylan Pharmaceuticals presented on Cimduo, Symfi, and Symfi-Lo drug medications and referenced detailed prescribing information handouts entitled “Cimduo”, “Symfi” and Symfi-Lo”.

Dr. Keiser asked for a motion to add or decline Cimduo, Symfi and Symfi-Lo drug medications to the THMP formulary.

Motion: Mr. Bruce Turner motioned to add the Symfi-Lo medication to the THMP drug formulary. Mr. Frank Rosas seconded the motion. Dr. Phillip Keiser asked for a verbal vote, and the motion carried with eight yea’s, no nays, and no abstentions.

Motion: Mr. Bruce Turner motioned to decline adding Cimduo and Symfi-Lo medications to the THMP drug formulary. Dr. Yolanda Rodriguez-Escobar seconded the motion. Dr. Phillip Keiser asked for a verbal vote, and the motion carried with eight yea’s, no nays, and no abstentions.


Agenda Item 8: Data Reports

Ms. Rachel Sanor, THMP Manager, DSHS, provided a data report. Highlights of data report discussion included:

  • The Governance and Data subcommittee will review the current data reports to focus the information presented.
  • The introduction of the new THMP data manager, Randy Gesn.


Agenda Item 9: Schedule Next Meeting/Public Comment 

Dr. Phillip Keiser led the discussion on the next meeting date, July 19, 2019 and referenced the Calendar handout for 2020. Highlights of the committee member discussion included:

  • Mr. Frank Rosas noted the Eligibility subcommittee will meet in May 2019 and will provide a report at the July 19, 2019 full committee meeting.

No Public Comment was offered during this agenda item.


Agenda Item 10: Adjournment

Dr. Phillip Keiser adjourned the meeting at 1:54 p.m.


Below is the link to the archived video of the April 5, 2019 Texas HIV Medication Advisory Committee meeting. (To view and listen to the entirety of the meeting click on the link below)

April 5, 2019 Texas HIV Medication Advisory Committee Meeting



Last updated April 29, 2021